PPAR-gamma and Vascular Lesion Formation

$370,090R01FY2013HLNIH

University Of Michigan At Ann Arbor, Ann Arbor MI

Investigators

Linked publications & trials

Paper 34796717 Paper 33538785 Paper 33507881 Paper 33418500 Paper 33339817 Paper 33297755 Paper 33268508 Paper 33097703 Paper 32787523 Paper 32678909 Paper 32671602 Paper 32404006 Paper 32354235 Paper 32188271 Paper 32132415 Paper 31553668 Paper 31074702 Paper 30772307 Paper 30602303 Paper 30248551 Paper 30153136 Paper 30026272 Paper 29954752 Paper 29578057 Paper 29473818 Paper 29467198 Paper 29413964 Paper 29403061 Paper 29371216 Paper 29361501 Paper 29141139 Paper 28555172 Paper 28428219 Paper 28228444 Paper 27571517 Paper 27511819 Paper 27294862 Paper 26988589 Paper 26847647 Paper 26774178 Paper 26746985 Paper 26709810 Paper 26586440 Paper 26368306 Paper 26117661 Paper 25277507 Paper 24833795 Paper 24633158 Paper 24403564 Paper 24386218 Paper 24338065 Paper 24324805 Paper 24301055 Paper 23567898 Paper 23502673 Paper 23422584 Paper 23408111 Paper 23360436 Paper 23334216 Paper 23264620 Paper 23241412 Paper 23060450 Paper 23042817 Paper 23028706 Paper 22855570 Paper 22545119 Paper 22411986 Paper 22240910 Paper 22127249 Paper 22096093 Paper 22039047 Paper 21990353 Paper 21971051 Paper 21677291 Paper 21502977 Paper 21439638 Paper 21382976 Paper 21205987 Paper 21088248 Paper 20799856 Paper 20673997 Paper 20630681 Paper 20558825 Paper 20498376 Paper 20445066 Paper 20118242 Paper 20097754 Paper 20053374 Paper 19901190 Paper 19602323 Paper 19364979 Paper 19221220 Paper 19196830 Paper 19118492 Paper 19061437 Paper 18795840 Paper 18604218 Paper 18467446 Paper 18056528 Paper 17678635

Abstract

DESCRIPTION (provided by applicant): Emerging data suggest that peroxisome proliferator-activated receptor- ? (PPAR-?) is a critical determinant that may provide functional links between diabetes and CVD. During the past cycle of this R01 funding, our laboratory has made a series of significant contributions to better understand the role of PPAR-? activation in the vasculature. The insulin-sensitizing thiazolidinediones (TZDs) are synthetic ligands of PPAR-? and the first drugs used to treat insulin resistance in patients with type 2 diabetes. Despite of their effectiveness as insulin sensitizers and their protective effects in the vasculature, the therapeutic efficacy of TZDs has been severely compromised due to the appearance of associated cardiovascular events. Thus, the investigation of the molecular mechanisms underlying PPAR-? functions especially in the cardiovascular system are of utmost importance. Of significance, we have identified a nitric oxide (NO) and fatty acid-derived product, nitrated derivatives of fatty acids (NO2-FA) including nitrated oleic acid (OA- NO2) and linoleic acid (LNO2), as potent endogenous PPAR ? ligands. More recent analysis by our laboratories clearly documented that NO2-FA-activated PPAR ? recruits/displaces differential cofactors leading to a pattern of gene expression that mediate different biological responses compared to TZD-activated PPAR ?. Also, we have identified Kruppel-like factor 11 (KLF11) as a novel PPAR3 cofactor. Although KLF11 gene mutations cause MODY7, an early-onset type 2 diabetes mellitus, but its role in the vasculature is entirely unknown. Based on these key results, in this proposal we will test the central hypothesis that NO2-FA-modulated PPAR ? activation and the recruitment of KLF11 play a critical role in protecting the vasculature from vascular lesion formation, thereby contributing to maintenance of vascular homeostasis. Specifically, we will 1) Determine the molecular interactions between NO2-FA and PPAR-? in vascular remodeling; 2) Define KLF11 as a novel PPAR-? cofactor required for PPAR-? function during vascular lesion formation. Advances in understanding the mechanisms of endogenous PPAR-? modulation will provide novel therapeutic strategies for treating diabetes and CVD.

View original record on NIH RePORTER →